140 related articles for article (PubMed ID: 3351001)
1. View from the Nation's Capital. FDA moves forward (and backwards) on a number of simmering issues.
Appler WD
J Clin Psychopharmacol; 1988 Feb; 8(1):57-8. PubMed ID: 3351001
[No Abstract] [Full Text] [Related]
2. View from the nation's capital.
Romansky MA
J Clin Psychopharmacol; 1985 Feb; 5(1):51-2. PubMed ID: 2982923
[No Abstract] [Full Text] [Related]
3. View from the Nation's Capital. New drug application (NDA) and investigational new drug (IND) regulations.
Romansky MA
J Clin Psychopharmacol; 1983 Dec; 3(6):380-3. PubMed ID: 6680409
[No Abstract] [Full Text] [Related]
4. View from the Nation's Capital. Investigational new drug (IND) and new drug application (NDA).
Romansky MA
J Clin Psychopharmacol; 1983 Jun; 3(3):193-4. PubMed ID: 6680405
[No Abstract] [Full Text] [Related]
5. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
[No Abstract] [Full Text] [Related]
6. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Feb; 4(1):52-4. PubMed ID: 6096407
[No Abstract] [Full Text] [Related]
7. Desperation drugs. Frustrated AIDs patients are spurring the FDA to relax the rules of the game.
Begley S; Hager M; Wilson L
Newsweek; 1989 Aug; 114(6):48-9, 51. PubMed ID: 10293942
[No Abstract] [Full Text] [Related]
8. View from the Nation's Capital.
Freishtat HW
J Clin Psychopharmacol; 1985 Apr; 5(2):117-9. PubMed ID: 3988970
[No Abstract] [Full Text] [Related]
9. The FDA takes action against unapproved drugs.
Meadows M
FDA Consum; 2007; 41(1):34-5. PubMed ID: 17342837
[TBL] [Abstract][Full Text] [Related]
10. FDA bans 223 ingredients in nonprescription drug products.
Clin Pharm; 1991 Feb; 10(2):88, 93. PubMed ID: 2009736
[No Abstract] [Full Text] [Related]
11. View from the Nation's Capital. FDA challenged successfully on its policies regarding good manufacturing practice inspections of medical drug and device manufacturers.
Appler WD
J Clin Psychopharmacol; 1987 Oct; 7(5):346-7. PubMed ID: 3680606
[No Abstract] [Full Text] [Related]
12. View from the Nation's Capitol.
Romansky MA
J Clin Psychopharmacol; 1982 Feb; 2(1):74-5. PubMed ID: 6926923
[No Abstract] [Full Text] [Related]
13. View from the Nation's Capital.
Appler WD
J Clin Psychopharmacol; 1986 Feb; 6(1):42-4. PubMed ID: 3950066
[No Abstract] [Full Text] [Related]
14. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
Lovell MC
Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
[No Abstract] [Full Text] [Related]
15. A faster track for AIDS drugs?
Kosterlitz J
Natl J (Wash); 1989 Jul; 21(30):1931. PubMed ID: 10293944
[No Abstract] [Full Text] [Related]
16. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403
[No Abstract] [Full Text] [Related]
17. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Oct; 4(5):288-9. PubMed ID: 6096409
[No Abstract] [Full Text] [Related]
18. New prescription for drug regulation.
Pines WL
FDA Consum; 1978 Jun; 12(5):7-10. PubMed ID: 10308117
[TBL] [Abstract][Full Text] [Related]
19. Panel recommends changes to expedite approval of cancer, AIDS drugs.
Am J Hosp Pharm; 1990 Nov; 47(11):2410, 2413. PubMed ID: 2278248
[No Abstract] [Full Text] [Related]
20. View from the Nation's Capitol.
Freishtat HW
J Clin Psychopharmacol; 1982 Apr; 2(2):146-8. PubMed ID: 6926924
[No Abstract] [Full Text] [Related]
[Next] [New Search]
